Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa G Lechner

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Current Cancer Reports|October 14, 2024
Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapyDayna Jill Isaacs, Nikhita Kathuria-Prakash, Robin Hilder, et al.
European Journal of Pharmacology|July 22, 2014
Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsisConstance N Wilson, Constance O Vance, Melissa G Lechner, et al.
The Oncologist|June 23, 2025
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancerAlexis LeVee, Esther Peluso, Melissa G Lechner, et al.
Immunological Reviews|January 24, 2026
Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti-Cancer Immunity Across the LifespanChristian G Bustillos, Esther M Peluso, Sophia L Cha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroTrevor E Angell, Melissa G Lechner, Julie K Jang, et al.
The Oncologist|September 1, 2020
Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-AnalysisMelissa G Lechner, Angeli C Bernardo, Alyssa Lampe, et al.
Journal of Translational Medicine|June 11, 2011
Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell linesMelissa G Lechner, Carolina Megiel, Sarah M Russell, et al.
The Oncologist|November 9, 2025
Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancerAlexis LeVee, Austin Kordic, Nora Ruel, et al.
Thyroid : Official Journal of the American Thyroid Association|June 24, 2014
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltrationTrevor E Angell, Melissa G Lechner, Julie K Jang, et al.
JCEM Case Reports|June 11, 2026
Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1Alexandra Lim, Esther M Peluso, Ian A Downs, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Current Cancer Reports|October 14, 2024
Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapyDayna Jill Isaacs, Nikhita Kathuria-Prakash, Robin Hilder, et al.
European Journal of Pharmacology|July 22, 2014
Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsisConstance N Wilson, Constance O Vance, Melissa G Lechner, et al.
The Oncologist|June 23, 2025
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancerAlexis LeVee, Esther Peluso, Melissa G Lechner, et al.
Immunological Reviews|January 24, 2026
Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti-Cancer Immunity Across the LifespanChristian G Bustillos, Esther M Peluso, Sophia L Cha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroTrevor E Angell, Melissa G Lechner, Julie K Jang, et al.
The Oncologist|September 1, 2020
Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-AnalysisMelissa G Lechner, Angeli C Bernardo, Alyssa Lampe, et al.
Journal of Translational Medicine|June 11, 2011
Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell linesMelissa G Lechner, Carolina Megiel, Sarah M Russell, et al.
The Oncologist|November 9, 2025
Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancerAlexis LeVee, Austin Kordic, Nora Ruel, et al.
Thyroid : Official Journal of the American Thyroid Association|June 24, 2014
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltrationTrevor E Angell, Melissa G Lechner, Julie K Jang, et al.
JCEM Case Reports|June 11, 2026
Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1Alexandra Lim, Esther M Peluso, Ian A Downs, et al.
Pageof 6